济南不到二分钟就射精(济南睾丸旁边很痛) (今日更新中)

BEIJING, Sept. 14 (Xinhuanet) -- Facebook unveiled a new feature called "smart lists" on Tuesday, giving its users an easier way to share photos, posts and updates with smaller groups of friends.The new function, which commences on Wednesday, borrows from the success of the Circles feature of Google+, which allows users to categorize friends into groups.With the new feature, Facebook can automatically put your friends into groups, with the first four being work, school, family and city, based on the information of colleges, workplaces and geographic locations in users' profiles.The feature is optional to use, and the lists are customizable."This is really something we have been working on for four years," Facebook director of product management Blake Ross told AFP, adding "We think this is the way people will make lists going forward."In the meantime, the social networking site has also come up with "close friends" and "acquaintances" options.People can read the updates of their "close friends" more prominently in their news feed and just big news of their "acquaintances", according to Naomi Gleit, the director of product at Facebook who worked on the new feature.

BEIJING, June 12 (Xinhua) -- A senior Chinese official has called the country's police to better serve the people when the Communist Party of China (CPC) is meeting the 90th founding anniversary.Zhou Yongkang, member of the Standing Committee of the Political Bureau of the CPC Central Committee, made the remark on Sunday evening in meeting with top 10 favorite police officers selected through a nationwide vote.The Ministry of Public Security (MOPS) and the China Central Television have jointly conducted My Favorite Police Officer Competition in the past eight years.This year's winners include 75-year-old detective Wu Guoqing, network security police officer Li Qing from Jiangsu Province, traffic police officer Wu Hao of Miao Nationality from Hunan Province, female SWAT team leader Pan Qin from Guizhou Province.Zhou said that this year's competition attracted more than 150 million online voters which means more and more people are supporting the activity, and all winners should cherish the honor and better serve the people on their own posts.The official called on police officers around the country to learn from the 10 favarite officers and other winners in the competition who have all made outstanding contribution to the security of the people and society.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

SINGAPORE, June 14 (Xinhua) -- Researchers from Singapore and China are conducting a research aimed at using different technologies to completely capture and convert carbon dioxide in industrial emissions into energy, local daily Lianhe Zaobao reported on Tuesday.The project, supported by the National Research Foundation (NSF) of Singapore, will make use of sunlight as well as photochemical and photosynthetic processes, the foundation said.The researchers involved in the five-year project are from China's Peking University and Singapore's National University of Singapore and the Nanyang Technological University. A research center will be established under the Campus for Research Excellence and Tehnological Enterprise, a program also known as CREATE, the foundation said.It will be the first project involving cooperation with a Chinese university under the program. It will be located at the University Town of the National University of Singapore due to be completed by the end of the year.Lee Yuan-Kun, a researcher at the National University of Singapore, said no single chemical process can capture and convert the carbon dioxide completely so the researchers will be first treating the emissions with photochemical and electrochemical processes to convert most of the carbon dioxide into energy resources such as methane.The gas with thinner carbon dioxide will then be used to grow microalgae, he said.Nevertheless, for the cost of renewable energy to be close to that of fossil fuel, the efficiency will have to be drastically improved by about five to 10 times, Lee said.The project is one of three energy research projects to be housed under the Campus for Research Excellence and Tehnological Enterprise program.Zhang Dongxiao, from the College of Engineering at Peking University, said that the research program seeks to develop energy efficient and environmentally friendly carbon capture technologies that can be applied in the manufacturing and chemical industries, and that it complements Peking University's strong capability in carbon storage."Reducing carbon intensity will not only benefit both countries in terms of cost competitiveness of products made, but also portrays a good image on our national responsibility to achieve a sustainable Earth," Zhang said. 

来源：资阳报